ReviewArthritis research & therapy2015
Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype.
Review in Arthritis research & therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed, 5 syntheses or guidelines pooled it, 209 citations in OpenAlex.
- Upadacitinib for axial spondyloarthritis: a meta-analysis of efficacy and safety.Clinical rheumatology · 2024Pooled it
- Dermatologists' Role in the Early Diagnosis of Psoriatic Arthritis: Expert Recommendations.Actas dermo-sifiliograficas · 2020Guideline
- Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.Annals of the rheumatic diseases · 2018Guideline
- Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture.American journal of human genetics · 2015Pooled it
- A Systematic Review Characterizing Psoriatic Arthritis Onset and Exacerbation in Patients Receiving Biologic Therapy.Journal of cutaneous medicine and surgeryPooled it
- Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease.Arthritis research & therapy · 2018Trial
- Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open-labelled, controlled pilot study.Arthritis research & therapy · 2018Trial
- Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritis.Arthritis research & therapy · 2017Trial
- Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis.Annals of the rheumatic diseases · 2017Trial
- Excess cardiovascular morbidity in psoriatic arthritis and cardioprotective effects of biologic dmards: a propensity-matched analysis.Scientific reports · 2026Article
- Diagnostic Accuracy of Interleukin-17A for Internal Derangements of Temporomandibular Joints in Patients with Spondyloarthritis.Biomedicines · 2026Article
- Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized Trials.Rheumatology and therapy · 2026Article
- B Cells Can Trigger the T-Cell-Mediated Autoimmune Response Against Melanocytes in Psoriasis.Cells · 2025Article
- Prevalence of Psoriatic Arthritis in Patients with Moderate-to-Severe Psoriasis in the Era of Biologics and Small Molecule Therapies.Journal of clinical medicine · 2025Article
- Psoriatic Arthritis: From Diagnosis to Treatment.Journal of clinical medicine · 2025Review
- TNF-alpha inhibitors reduce the incidence of PsA in patients with psoriasis: a propensity score-matched cohort study.Rheumatology (Oxford, England) · 2025Article
- The relationship between vitamin D receptor (VDR) genomic polymorphisms, disease activity, and functional ability in patients with psoriatic arthritis.Clinical rheumatology · 2025Article
- Derivation of a Multivariable Psoriatic Arthritis Risk Estimation Tool (PRESTO): A Step Towards Prevention.Arthritis & rheumatology (Hoboken, N.J.) · 2025Article
- Temporomandibular Internal Derangements Denote Activity of Axial Spondyloarthritis.Acta stomatologica Croatica · 2025Article
- Immune response and cytokine pathways in psoriatic arthritis: A systematic review.Archives of rheumatology · 2025Review
35 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review focuses on the genetic features of psoriatic arthritis (PsA) and their relationship to phenotypic heterogeneity in the disease, and addresses three questions: what do the recent studies on human leukocyte antigen (HLA) tell us about the genetic relationship between cutaneous psoriasis (PsO) and PsA - that is, is PsO a unitary phenotype; is PsA a genetically heterogeneous or homogeneous entity; and do the genetic factors implicated in determining susceptibility to PsA predict clinical phenotype? We first discuss the results from comparing the HLA typing of two PsO cohorts: one cohort providing the dermatologic perspective, consisting of patients with PsO without evidence of arthritic disease; and the second cohort providing the rheumatologic perspective, consisting of patients with PsA. We show that these two cohorts differ considerably in their predominant HLA alleles, indicating the heterogeneity of the overall PsO phenotype. Moreover, the genotype of patients in the PsA cohort was shown to be heterogeneous with significant elevations in the frequency of haplotypes containing HLA-B*08, HLA-C*06:02, HLA-B*27, HLA-B*38 and HLA-B*39. Because different genetic susceptibility genes imply different disease mechanisms, and possibly different clinical courses and therapeutic responses, we then review the evidence for a phenotypic difference among patients with PsA who have inherited different HLA alleles. We provide evidence that different alleles and, more importantly, different haplotypes implicated in determining PsA susceptibility are associated with different phenotypic characteristics that appear to be subphenotypes. The implication of these findings for the overall pathophysiologic mechanisms involved in PsA is discussed with specific reference to their bearing on the discussion of whether PsA is conceptualised as an autoimmune process or one that is based on entheseal responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.